Benefits
Urinary tract health
Cranberry products have been tested in dozens of trials. Pooled results showed fewer repeat urinary infections in women who get them often, in children and after some medical procedures, but showed little effect in older adults in care homes or in pregnancy. Questions remain about dose and duration, and no trial has tested this product.
Anti-adhesion action
Cranberry proanthocyanidins (PACs) inhibit the attachment of P-fimbriated E. coli to cells lining the bladder in lab studies. This is the leading proposed mechanism rather than a proven one, and nothing cited on this page tested whether this product does it in people.
Mechanism of action
Proanthocyanidins (PACs)
Cranberry PACs inhibit the adherence of P-fimbriated E. coli to the cells lining the bladder in lab studies, so fewer bacteria may attach. PAC content varies between cranberry products and is not stated for this product, and pooled trials could not show a difference between low and high PAC doses.
Clinical trials
Cochrane systematic review of randomized and quasi-randomized trials of cranberry juice, tablets or capsules versus placebo, no treatment or other options, searched to March 2023. (Williams et al. 2023, Cochrane Database Syst Rev)
50 trials with 8,857 participants, including women with recurrent infections, children, older adults in care, pregnant women and people after medical procedures.
Cranberry products reduced symptomatic, culture-verified infections overall (RR 0.70, 95% CI 0.58 to 0.84) and in women with recurrent infections (8 trials, 1,555 people, RR 0.74, 95% CI 0.55 to 0.99). There was little or no benefit in elderly institutionalized people or pregnant women. Effects of different PAC doses were unclear. Gastrointestinal side effects probably did not differ from placebo.